Jon Cuthbert

SPAR Group (NASDAQ:SGRP) issued optimistic financial guidance for fiscal year 2026 on Tuesday, March 31, 2026, signaling a major turn toward higher profitability and operational efficiency.

Palvella Therapeutics (NASDAQ:PVLA) reported transformative full-year 2025 financial results and a significant corporate update on March 31, 2026, headlined by the successful clinical validation of its lead rare disease program.

TD SYNNEX (NYSE:SNX) reported exceptional financial results for the fiscal first quarter ended February 28, 2026, significantly outperforming its previous guidance across all major metrics.

iHuman (NYSE:IH) reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, revealing a cooling in top-line growth even as the company remains profitable and committed to shareholder returns.

Oculis (NASDAQ:OCS) announced on March 31, 2026, that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation to Privosegtor for the treatment of optic neuritis.

Two US senators have pressed the Securities and Exchange Commission for answers following the resignation of enforcement director Margaret Ryan amid concerns over politically sensitive crypto cases.

UK investors buying Strategy’s STRC preferred stock may face significantly higher taxes than expected, as distributions are treated as dividends rather than tax-deferred returns.

BitMine Immersion Technologies has made its largest ether purchase of 2026, acquiring 71,179 ETH worth roughly $143 million as it continues aggressive accumulation.

Trump-backed American Bitcoin has expanded its Bitcoin reserves to 7,000 BTC, roughly tripling its holdings since its Nasdaq debut in September 2025.

Veteran trader Peter Brandt said Bitcoin is unlikely to reach a new all-time high in 2026, suggesting the next peak may not arrive until the second quarter of 2027.